{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975806",
  "id": "02975806",
  "pages": 44,
  "price_sensitive": false,
  "date": "20250801",
  "time": "0943",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250801/pdf/06mf720y5x85kf.pdf",
  "summary": "### **Material Information Summary: ASX Prospectus - Amplia Therapeutics Limited (ASX: ATX)**  \n\n#### **Capital Raising Overview**  \n\u0421\u0442\u0430\u0442\u0443\u0441: **Share Purchase Plan (SPP)**  \n- **Structure**: SPP + SPP Shortfall Offer (for institutional investors if undersubscribed).  \n- **Target Raise**: **A$2.5M** (with ability to accept oversubscriptions up to **A$10M total**).  \n- **SPP Price**: Lower of:  \n  - Fixed price of **A$0.23/share** (Placement Offer Price), or  \n  - **5% discount** to 5-day VWAP before Closing Date.  \n- **Key Dates**:  \n  - **Record Date**: 22 July 2025.  \n  - **Closing Date**: 22 August 2025.  \n  - **Results Announcement**: 26 August 2025.  \n  - **AGM (Approval)**: 27 August 2025.  \n  - **Trading of New Shares**: Expected 1 September 2025.  \n\n#### **Use of Proceeds**  \nTotal raised funds (up to **A$27.5M** before costs) will be allocated to:  \n- **Clinical Trials**:  \n  - ACCENT (Phase 2a pancreatic cancer trial completion).  \n  - AMPLICITY (dose escalation/comparison).  \n  - Initiation of kRAS and ovarian cancer trials.  \n- **Manufacturing (CMC)**: **A$6M**.  \n- **Working capital & costs**.  \n\n#### **Capital Structure Impact**  \n- **Current Shares Outstanding**: 486.5M.  \n- **New Shares Issued**: Up to 43.5M (if SPP reaches A$10M at A$0.23/share).  \n- **Market Cap (at A$0.23)**: **A$117M\u2013125M** (depending on raise size).  \n\n#### **Key Risks**  \n- **Clinical Trials**: No guarantee of success; topline data for ACCENT due August 2025.  \n- **Funding**: Future capital needs may dilute shareholders.  \n- **Regulatory**: Approval risks for trials/commercialization.  \n- **R&D Tax Rebate**: Reliance on government incentives (~A$8.2M expected).  \n\n#### **Additional Material Details**  \n- **Lead Manager**: Bell Potter Securities (not underwritten but backstopped for A$2.5M shortfall).  \n- **Eligibility**: Shareholders in AU/NZ as of 22 July 2025; max **A$100k per holder**.  \n- **Dilution**: Non-participating shareholders face dilution (up to ~9% at full raise).  \n\n#### **Action Required**  \nEligible shareholders must apply via BPAY/EFT by **22 August 2025**.  \n\n**No material omissions or discrepancies identified.**  \n\n---  \n*Tailored for trading/capital markets decisions; excludes legal boilerplate, director details, and routine disclosures.*",
  "usage": {
    "prompt_tokens": 24146,
    "completion_tokens": 645,
    "total_tokens": 24791,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T23:53:44.727164"
}